Spondyloarthropathies

Top Story

Secukinumab demonstrates sustained response, consistent safety profile in AS

Secukinumab demonstrates sustained response, consistent safety profile in AS
November 17, 2017

SAN DIEGO — Secukinumab provided sustained improvements in signs and symptoms of ankylosing spondylitis among patients who completed three years of treatment, according to data presented at the American College of Rheumatology Annual Meeting.

In addition to sustained improvements in physical function at 3 years, secukinumab also demonstrated a safety profile consistent with previous data for this population.

Meeting News

Monoclonal antibody shown to be safe, effective in managing PsA

November 16, 2017
SAN DIEGO – Treatment with ABBV-066, a monoclonal antibody that inhibits interleukin-23, provided substantial improvements in joint and skin scores among patients…
Meeting NewsVideo

VIDEO: Adalimumab appears effective in non-radiographic axial spondyloarthropathy

November 15, 2017
SAN DIEGO – Treatment with adalimumab led to remission and sustained disease control among patients with non-radiographic axial spondyloarthropathy, according to…
Meeting News

MRI reveals sacroiliac inflammation in both healthy runners, patients with spondyloarthritis

November 10, 2017
SAN DIEGO — Although sacroiliac MRI has been extensively relied on to diagnose axial spondyloarthritis, research presented at the American College of Rheumatology…
More Headlines »
Advertisement
Advertisement